Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Decibel Therapeutics Inc. has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 5 actions are distributed among 5 distinct examiners, meaning each action is being handled by a different individual. These matters are spread across 4 distinct art units, suggesting a varied technical scope within the Biotechnology & Pharmaceuticals field. RAHMAN, MASUDUR is the busiest examiner, though they only have 1 pending action.
This reflects a perfectly even distribution of the workload across the 5 examiners. The high ratio of examiners and art units to the total number of actions indicates a diversified prosecution landscape for the company. For a practitioner, this means that the 5 pending office actions require managing 5 separate examiner relationships. The 1 pending action under RAHMAN, MASUDUR is just one part of this distributed strategy. This structure ensures that each matter receives specialized attention from a different examiner across 4 different art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
| O'NEILL, MARISOL ANN | 1 | 54.5% | +68.2% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
| SINGH, ANOOP KUMAR | 1 | 43.2% | +67.7% |
| TRAN, CHRISTINA L | 1 | 51.6% | +49.8% |
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278053 | METHODS AND COMPOSITIONS FOR REDUCING NUCLEIC ACID VECTOR-INDUCED TOXICITY IN THE INNER EAR | KONOPKA, CATHERINE ANNE | — |
| 17924578 | COMPOSITIONS AND METHODS FOR PROMOTING HAIR CELL REGENERATION | SINGH, ANOOP KUMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17413223 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS ACROSS THE ROUND WINDOW MEMBRANE | REYNOLDS, FRED H | 28d |
| 17794673 | METHODS AND COMPOSITIONS FOR GENERATING TYPE 1 VESTIBULAR HAIR CELLS | TRAN, CHRISTINA L | 62d |
| 19027519 | MYOSIN 15 PROMOTERS AND USES THEREOF | RAHMAN, MASUDUR | — |
| 18444107 | METHODS AND COMPOSITIONS FOR ADMINISTERING OTOFERLIN DUAL VECTOR SYSTEMS | O'NEILL, MARISOL ANN | — |
| 18278053 | METHODS AND COMPOSITIONS FOR REDUCING NUCLEIC ACID VECTOR-INDUCED TOXICITY IN THE INNER EAR | KONOPKA, CATHERINE ANNE | — |
| 17924578 | COMPOSITIONS AND METHODS FOR PROMOTING HAIR CELL REGENERATION | SINGH, ANOOP KUMAR | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| 1635 | 1 |
| 1632 | 1 |
| 1637 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19027519 | MYOSIN 15 PROMOTERS AND USES THEREOF | RAHMAN, MASUDUR | 1633 | DP | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18444107 | METHODS AND COMPOSITIONS FOR ADMINISTERING OTOFERLIN DUAL VECTOR SYSTEMS | O'NEILL, MARISOL ANN | 1633 | §103DP | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18278053 | METHODS AND COMPOSITIONS FOR REDUCING NUCLEIC ACID VECTOR-INDUCED TOXICITY IN THE INNER EAR | KONOPKA, CATHERINE ANNE | 1635 | §102§103§112 | Final Rejection | — | Pending | Aug 21, 2023 |
| 17924578 | COMPOSITIONS AND METHODS FOR PROMOTING HAIR CELL REGENERATION | SINGH, ANOOP KUMAR | 1632 | §102§103§112 | Final Rejection | — | Pending | Nov 10, 2022 |
| 17794673 | METHODS AND COMPOSITIONS FOR GENERATING TYPE 1 VESTIBULAR HAIR CELLS | TRAN, CHRISTINA L | 1637 | §112 | Non-Final OA | 62d | Pending | Jul 22, 2022 |
| 17413223 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS ACROSS THE ROUND WINDOW MEMBRANE | REYNOLDS, FRED H | 1658 | §103 | Non-Final OA | 28d | Pending | Jun 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDecibel Therapeutics Inc. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Masudur Rahman has the most, with 1 of Decibel Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
